The Biopharma Pod William Reed Business Media

Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth, in CGT in particular.

Today we are launching a new series called The BioPharma Pod. Kicking off these broadcasts is the hot topic of biosimilars.

A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.

Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.

The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.

Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.